23:55 , Apr 28, 2017 |  BioCentury  |  Politics, Policy & Law

Access and innovation in Japan

Regulatory reforms have paved the way for innovative therapies to launch in Japan before anywhere else in the world. This should result in earlier access to more innovative medicines than ever before - but only...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Chugai, Kowa, Sanofi deal

Kowa and Chugai expanded a 2012 deal to develop Chugai’s diabetes drug Deberza tofogliflozin hydrate in Japan. Chugai now granted Kowa exclusive rights to develop and commercialize the sodium-glucose cotransporter 2 (SGLT2) inhibitor to treat...
07:00 , May 6, 2013 |  BioCentury  |  Strategy

Doubling down in diabetes

Against a backdrop of flattening sales of its only marketed diabetes drugs and a new class of oral drugs - SGLT2s - entering the market from competitors, Merck & Co. Inc. appears to be shoring...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Company News

Chugai, Kowa, Sanofi deal

Chugai granted Kowa and Sanofi rights to co-develop Chugai's diabetes compound CSG452 in Japan. The three partners will co-develop the product, while Kowa and Sanofi will be responsible for submitting regulatory applications. Chugai, which will...
00:22 , Oct 30, 2012 |  BC Extra  |  Company News

Chugai to co-develop diabetes candidate in Japan with Kowa, Sanofi

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) granted Kowa Co. Ltd. (Nagoya, Japan) and Sanofi (Euronext:SAN; NYSE:SNY) rights to co-develop Chugai's diabetes compound CSG452 in Japan. The three partners will co-develop the sodium-glucose cotransporter 2 (SGLT2) inhibitor,...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

Chugai, Roche deal

Roche terminated a 2007 deal and returned ex-Japanese rights to diabetes candidate CSG452 to Chugai. Roche made the decision after reviewing the priority of its development pipeline, according to Chugai. The sodium-glucose cotransporter 2 (SGLT2)...
23:54 , Jul 5, 2011 |  BC Extra  |  Company News

Roche returns rights to Chugai for diabetes candidate

Roche (SIX:ROG; OTCQX:RHHBY) returned ex-Japanese rights to diabetes candidate CSG452 to Chugai Pharmaceutical Co. Ltd. (Tokyo:4519). Roche, which gained the product through a 2007 deal, made the decision after reviewing the priority of its development...
08:00 , Jan 25, 2010 |  BioCentury  |  Product Development

SGLT2 Pipeline

SGLT2 Pipeline Company Product Status AstraZeneca plc (LSE:AZN; NYSE:AZN)/ Bristol-Myers Squibb Co. (NYSE:BMY) Dapagliflozin Ph III Johnson & Johnson (NYSE:JNJ)/Mitsubishi Tanabe Pharma Corp. (Tokyo:4530; Osaka:4530) Canagliflozin Ph III Astellas Pharma Inc. (Tokyo:4503)/ Kotobuki Pharmaceutical Co....
07:00 , Apr 27, 2009 |  BC Week In Review  |  Clinical News

R7201: Phase IIb started

Roche disclosed that in February it began a double-blind, placebo-controlled, international Phase Ilb trial to evaluate 5 dose levels of oral R7201 given daily for 12 weeks in 300 patients. Roche licensed the compound in...